Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to proven pharmacological agents.
Our portfolio includes two products approved by the US Food and Drug Administration, SUSTOL® (granisetron) extended release injection and CINVANTITM (aprepitant) injectable emulsion, as well as one product in development; HTX-011, a novel fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam being investigated for application into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours.